AbbVie Inc. $ABBV Shares Newly Purchased by B.A. Schrock Wealth Management Inc.

B.A. Schrock Wealth Management Inc. purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 33,286 shares of the company’s stock, valued at approximately $8,652,000. AbbVie comprises about 2.9% of B.A. Schrock Wealth Management Inc.’s investment portfolio, making the stock its 5th largest position.

Other institutional investors have also recently added to or reduced their stakes in the company. Howard Financial Services LTD. raised its position in AbbVie by 8.2% in the 3rd quarter. Howard Financial Services LTD. now owns 4,504 shares of the company’s stock worth $1,178,000 after purchasing an additional 342 shares during the last quarter. Mather Group LLC. lifted its holdings in AbbVie by 5.6% during the 3rd quarter. Mather Group LLC. now owns 35,883 shares of the company’s stock worth $9,387,000 after buying an additional 1,893 shares in the last quarter. First Pacific Financial lifted its holdings in AbbVie by 1.1% during the 3rd quarter. First Pacific Financial now owns 28,144 shares of the company’s stock worth $7,362,000 after buying an additional 294 shares in the last quarter. MPS Loria Financial Planners LLC boosted its position in AbbVie by 0.6% in the 3rd quarter. MPS Loria Financial Planners LLC now owns 16,160 shares of the company’s stock valued at $4,227,000 after buying an additional 95 shares during the last quarter. Finally, Fortitude Family Office LLC boosted its position in AbbVie by 7.7% in the 3rd quarter. Fortitude Family Office LLC now owns 4,552 shares of the company’s stock valued at $1,191,000 after buying an additional 327 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $283.58 on Thursday. The firm’s 50 day simple moving average is $261.16 and its 200 day simple moving average is $238.38. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $285.40. The company has a market capitalization of $501.03 billion, a price-to-earnings ratio of 80.11, a P/E/G ratio of 1.25 and a beta of 0.24.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the prior year, the firm earned $2.97 earnings per share. The business’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts expect that AbbVie Inc. will post 13.95 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive SKYRIZI Crohn’s disease data: Phase 3 AFFIRM results showed that subcutaneous SKYRIZI produced meaningful clinical and endoscopic benefits versus placebo, with a safety profile consistent with the established treatment. The data could support regulatory review of a more convenient induction option and strengthen AbbVie’s post-Humira growth franchise. Did SKYRIZI’s Subcutaneous Crohn’s Data Just Shift AbbVie’s Investment Narrative?
• Positive Sentiment: Analyst and earnings optimism: RBC reaffirmed an “outperform” rating and cited potential third-quarter strength from RINVOQ, SKYRIZI, and Vraylar. Erste Group also raised its FY2027 EPS estimate to $16.34 from $16.19 while maintaining a “Buy” rating. Investors are looking ahead to AbbVie’s October 30 earnings report. AbbVie Poised for Q3 Top-Line Beat
• Positive Sentiment: Broad healthcare rally and options activity: Pharmaceutical stocks rallied broadly, supporting ABBV. Investors also purchased 86,296 AbbVie call options, approximately 445% above typical call volume, indicating elevated bullish positioning, although options activity alone does not guarantee further gains. Lilly, Merck, AbbVie Stocks Surge
• Neutral Sentiment: Mixed comparative view: A Zacks analysis argued that Sanofi currently offers a more attractive combination of valuation, outlook, and Dupixent growth, suggesting AbbVie’s strong recent performance has left less valuation upside relative to some peers. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
• Negative Sentiment: Valuation and conflicting market reaction: One report characterized ABBV as trading above estimated fair value, while another described an initial decline following the new SKYRIZI data. The conflicting reactions highlight execution, regulatory, and valuation risks despite the data’s long-term potential. A Look at AbbVie After a Decline

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. UBS Group lifted their target price on AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research note on Tuesday, October 6th. Cantor Fitzgerald upped their price target on AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. BMO Capital Markets upped their price target on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Weiss Ratings upgraded AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Finally, Barclays lifted their price objective on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $277.18.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.